

49. Powell, L. C., Guest, M. M., and Bond, T. P. Coagulation and fibrinolytic studies in women receiving an anovulatory drug. *Amer J Obstet Gynec* 93:167, 1965.
50. Rapaport, S. I. Proceedings of a conference: thromboembolic phenomena in women. p. 154, Chicago, G. D. Searle & Co., 1962.
51. Ratnoff, O. D. and Holland, T. R. Coagulation components in normal and abnormal pregnancies. *Ann NY Acad Sci* 75:626, 1959.
52. Reed, D. L. and Coon, W. W. Thromboembolism in patients receiving progestational drugs. *New Eng J Med* 269:622, 1963.
53. Robinson, R. W. Effects of estrogen-progestin combinations on clotting factors. *Amer J Obstet Gynec* 99:163, 1967.
54. Rona, G. The role of vascular mucopolysaccharides in the hemostatic action of estrogens. *Amer J Obstet Gynec* 87:434, 1963.
55. Rona, G. Experimental studies on vascular purpura and capillary hemostasis. *Rev. Canad Biol* 22:465, 1963.
56. Rutherford, R. N., Hougie, C., Banks, A. L., and Coburn, W. A. The effects of sex steroids and pregnancy on blood coagulation factors. *Obstet Gynec* 24:886, 1964.
57. Salvadori, B., Cagnazzo, G., Ciasca, G., and Giorgino, R. Progesteroidi di sintesi ed emocoagulazione. *Ann Obstet Ginec* 82:705, 1960.
58. Samuels, A. J., Lepowsky, F., and Tyler, E. Assay of selected hematologic and coagulation factors in patients on Provera. *Int J Fertil* 8:665, 1963.
59. Schersten, B. Remarks on hemostatics with special reference to their clinical use. *Suom Laak lehti* 13:855, 1958.
60. Schiff, M. and Burns, H. F. The effect of estrogens on mast cells and enzymes in connective tissue metabolism in humans. *Laryngoscope* 71:766, 1961.
61. Schrogie, J. J. and Solomon, H. M. Estrogenic hormones and blood coagulation. *J Chronic Dis* 20:675, 1967.
62. Schrogie, J. J., Solomon, H. M., and Zieve, P. D. Effect of oral contraceptives on vitamin K-dependent clotting activity. *Clin Pharmacol Ther* 8:670, 1967.
63. Shaper, A. G., McIntosh, D. M., and Evans, C. M. Fibrinolysis and plasminogen levels in pregnancy and the puerperium. *Lancet* 2:706, 1965.
64. Sobrero, A. J., Fenichel, R. L., and Singher, H. O. Effects of a progestin-estrogen preparation on blood coagulation mechanisms. *JAMA* 185:136, 1963.
65. Talbert, L. M., and Langdell, R. D. Normal values of certain factors in the blood clotting mechanism in pregnancy. *Amer J Obstet Gynec* 90:44, 1964.
66. Thomson, J. M. and Poller, L. Oral contraceptive hormones and blood coagulability. *Brit Med J* 2:270, 1965.
67. Todd, M. E., Thompson, J. H., Jr., and Bowie, E. J. Changes in blood coagulation during pregnancy. *Mayo Clin Proc* 40:370, 1965.
68. Wright, H. P. Changes in the adhesiveness of blood platelets following parturition and surgical operations. *J Path Bact* 54:461, 1942.
69. Ygge, J., Brody, S., Korsan-Bengtson, K., and Nilsson, L. Changes in blood coagulation and fibrinolysis in women receiving oral contraceptives. *Amer J Obstet Gynec* 104:87, 1969.
70. Young, C. C., Mammen, E. F., and Spain, W. T. The effect of sequential hormone therapy on the reproductive cycle. *Pacif Med Surg* 73:35, 1965.

E. CEREBROVASCULAR DISEASES ASSOCIATED WITH THE USE OF ORAL
CONTRACEPTIVES: A REVIEW OF THE LITERATURE

Alfonse T. Masi, M.D., Dr. P. H. and M. Dugdale, M.D.

Numerous clinical reports indicate that neurologic complications may result from the use of oral contraceptives. These include vascular occlusive syndromes of the central nervous system and retina, migraine and other assorted cerebrovascular disorders. Retrospective epidemiologic studies by British investigators have demonstrated an etiologic relation between the use of oral contraceptives and idiopathic cerebrovascular disease. There is no evidence however, that the overall incidence of death or morbidity from cerebrovascular